Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice
- PMID: 17285097
Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice
Abstract
This double-blind, multicenter trial, carried out in general practice in Denmark, comprised 221 women and 70 men, aged 58 to 97 years, with major depression (with or without mild cognitive dysfunction) or dysthymia (DSM-III-R). Patients had a total score > or =13 on the 17-item Hamilton Depression Rating Scale (HDRS) and a score > or =20 on the Mini Mental State Examination scale. The efficacy and tolerability of citalopram (20-40 mg daily) and amitriptyline (50-100 mg daily) were compared over 12 weeks. The participating general practitioners were trained at corating sessions in the use of the HDRS and Melancholia Scale (MES) prior to and during the study. The inter-observer reliability was assessed to investigate if general practitioners were able to use scales that measure the severity of depression. The two treatments were considered equally effective; the 90% confidence interval for the difference between the treatment groups in change from baseline to end-point in HDRS total score (-0.84 to +1.23) was within the predefined interval (-4 to +4). Significantly more patients on citalopram (50%) than on amitriptyline (31%) reported no adverse events at all (P = .001). Moreover, patients on amitriptyline reported adverse events significantly earlier and more frequently than patients on citalopram. The inter-observer reliability was highly satisfactory, with intra-class correlation coefficients (ICC-U) of .83 for the HDRS and .82 for the MES; however, the ICC-U for the Clinical Global Impressions was .54, indicating a poorer consensus in the investigators clinical judgment. Training in the use of the HDRS and MES scales improved the inter-observer reliability.
Similar articles
-
Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.Clin Ther. 2007 Nov;29(11):2319-32. doi: 10.1016/j.clinthera.2007.11.014. Clin Ther. 2007. PMID: 18158074 Clinical Trial.
-
Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.J Clin Psychopharmacol. 2006 Apr;26(2):121-7. doi: 10.1097/01.jcp.0000204138.20417.c3. J Clin Psychopharmacol. 2006. PMID: 16633139 Clinical Trial.
-
A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms.Contemp Clin Trials. 2009 May;30(3):205-11. doi: 10.1016/j.cct.2009.01.007. Epub 2009 Jan 24. Contemp Clin Trials. 2009. PMID: 19470312 Clinical Trial.
-
[Severe forms of depression: the efficacy of escitalopram].Encephale. 2009 Apr;35(2):152-9. doi: 10.1016/j.encep.2008.09.008. Epub 2009 Mar 31. Encephale. 2009. PMID: 19393384 Review. French.
-
[Suspected depression].MMW Fortschr Med. 2006 Aug 17;148(33-34):58-9. doi: 10.1007/BF03364709. MMW Fortschr Med. 2006. PMID: 16981394 Review. German. No abstract available.
Cited by
-
Pathological laughing and crying : epidemiology, pathophysiology and treatment.CNS Drugs. 2008;22(7):531-45. doi: 10.2165/00023210-200822070-00001. CNS Drugs. 2008. PMID: 18547124 Review.
-
Effects of SSRI Antidepressants on Attentional Bias toward Emotional Scenes in First-Episode Depressive Patients: Evidence from an Eye-Tracking Study.Psychiatry Investig. 2020 Sep;17(9):871-879. doi: 10.30773/pi.2019.0345. Epub 2020 Sep 17. Psychiatry Investig. 2020. PMID: 32933239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous